Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,059
  • Shares Outstanding, K 55,487
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,870 K
  • 60-Month Beta 1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.13
  • Number of Estimates 3
  • High Estimate -0.12
  • Low Estimate -0.14
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.82 +30.77%
on 10/23/19
2.68 -11.19%
on 11/11/19
+0.43 (+22.05%)
since 10/15/19
3-Month
1.82 +30.77%
on 10/23/19
2.77 -14.08%
on 09/11/19
unch (unch)
since 08/15/19
52-Week
1.57 +51.59%
on 03/06/19
3.13 -23.96%
on 07/19/19
+0.32 (+15.53%)
since 11/15/18

Most Recent Stories

More News
Aptose to Present at BIO-Europe Conference

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose...

APTO : 2.38 (-3.25%)
Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

- Company to Hold Event During ASH -

APTO : 2.38 (-3.25%)
Aptose Reports Results for the Third Quarter Ended September 30, 2019

CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate

APTO : 2.38 (-3.25%)
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and...

APTO : 2.38 (-3.25%)
Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today...

APTO : 2.38 (-3.25%)
Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today...

APTO : 2.38 (-3.25%)
Aptose Reports Results for the Second Quarter Ended June 30, 2019

- APTO-253 Inhibits MYC in AML and MDS Patients in Phase 1 Clinical Trial -

APTO : 2.38 (-3.25%)
Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice,...

APTO : 2.38 (-3.25%)
Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and...

APTO : 2.38 (-3.25%)
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

- CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML -

APTO : 2.38 (-3.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade APTO with:

Business Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in...

See More

Key Turning Points

2nd Resistance Point 2.48
1st Resistance Point 2.43
Last Price 2.38
1st Support Level 2.35
2nd Support Level 2.31

See More

52-Week High 3.13
Fibonacci 61.8% 2.53
Last Price 2.38
Fibonacci 50% 2.35
Fibonacci 38.2% 2.17
52-Week Low 1.57

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar